NHS Approves First Drug to Delay Type 1 Diabetes
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NICE has recommended teplizumab for NHS use in England and Wales — the first drug to delay onset of type 1 diabetes, giving patients roughly three extra years before needing lifelong insulin.
- Teplizumab is a 14-day IV infusion given to people aged 8+ whose blood tests show their immune system has started attacking insulin-producing pancreatic cells.
- Around 1,100 adults and children could be eligible in the first year, with roughly 820 per year offered it in the longer term once initial demand clears.
- The published list price is ~£150,000 per course, though the NHS negotiated a confidential discount with drugmaker Sanofi.
- The Scottish Medicines Consortium expects to issue advice on teplizumab in early 2027, and NICE guidance does not automatically apply in Northern Ireland.
- No routine NHS screening exists for early-stage type 1 diabetes — Italy is the only country with a national screening programme — so most eligible patients must currently be identified through incidental blood tests or family history.
- Charity Breakthrough T1D called the decision "momentous" and said further immunotherapy treatments are in development, with the long-term hope of personalised combination therapy eliminating insulin dependence.
Why it matters: Around 820 children and adults per year in England and Wales will gain roughly three years free from insulin injections, but the £150,000 list price — discounted via a confidential deal with Sanofi — combined with the absence of routine NHS screening for early immune attack means the drug's reach depends entirely on how many at-risk patients can be identified before symptoms appear.
Ask SkimNews
